Pharnext

Pioneering PLEOTHERAPY™ for neurodegenerative diseases

Issy-les-Moulineaux, France · Founded 2007 · $95.3M raised

Employees
11–50
Founded
2007
Business Model
B2B
Total Funding
$95.3M
Last Round
$5.3M Series AJun 2021
Rounds
2

About

Pharnext is an advanced clinical-stage biopharmaceutical company founded in 2007 by renowned scientists including Professor Daniel Cohen, a pioneer of modern genomics. The company develops novel therapeutics for orphan and common neurodegenerative diseases — including Charcot-Marie-Tooth disease type 1A, Alzheimer's disease, Parkinson's disease, and ALS — for which there are currently no cures. Pharnext pioneered PLEOTHERAPY™, a new drug discovery paradigm using network pharmacology and genomic data to identify synergistic combinations of already-approved drugs repurposed at optimal doses for new indications. Its lead candidate PXT3003 showed positive Phase 2 and Phase 3 results in CMT1A, and PXT864 generated encouraging Phase 2 data in Alzheimer's disease.

Summary

Pharnext is a Biotech company based in Issy-les-Moulineaux, France, founded in 2007. It has raised $95.3M in total across 2 rounds, most recently a $5.3M Series A round in Jun 2021. Investors include Truffle Capital and IPF Partners.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

ConvertibleConvertible NoteJun 2021
$90.0M

Sign up to see all 3 rounds

Series A through Convertible Note — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pharnext on Indexed.vc
<a href="https://indexed.vc/companies/pharnext"><img src="https://indexed.vc/api/badge/company/pharnext" alt="Pharnext on Indexed.vc" width="260" height="76" /></a>